The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | An update on Celestial-TNCLL: fixed-duration sonrotoclax plus zanubrutinib in CLL
Piers Patten, MB ChB, MRCP, FRCPath, PhD, King’s College London, London, UK, comments on the Phase III Celestial-TNCLL study (NCT06073821), an ongoing trial comparing the efficacy of a fixed-duration combination of sonrotoclax and zanubrutinib to the standard of care arm of venetoclax and obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia (CLL). Dr Patten highlights that the trial has almost completed enrolment across several countries, with a readout expected at some point in the next few years. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
CELESTIAL treatment-naive study is looking at the second generation agents of zanubrutinib and sonrotoclax, that’s a BTK inhibitor and a BCL2 inhibitor respectively, as a combination therapy, fixed duration, comparing it to the standard of care arm, which is 12 months duration of venetoclax-obinutuzumab. This is a major global study, which is recruiting actually extremely well and actually will stop recruitment pretty soon in 2025...
CELESTIAL treatment-naive study is looking at the second generation agents of zanubrutinib and sonrotoclax, that’s a BTK inhibitor and a BCL2 inhibitor respectively, as a combination therapy, fixed duration, comparing it to the standard of care arm, which is 12 months duration of venetoclax-obinutuzumab. This is a major global study, which is recruiting actually extremely well and actually will stop recruitment pretty soon in 2025. There wasn’t a specific update at ASH except just to show the countries where recruitment has occurred. So that’s North America, some countries in South America, in Europe, and also in Australasia. So it’s got a global footprint, so it’ll be relevant for all patients with CLL. Recruitment is now close to completion or may even have actually completed. And we will then be looking for a readout in the next few years. I can’t at this time tell you exactly when that will be, but anticipated later in the next few years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Novartis: Research Funding; Janssen: Honoraria, Other: Travel, accommodations, expenses, Research Funding; BeiGene: Honoraria, Other: Travel, accommodations, expenses, Research Funding; AbbVie: Honoraria, Other: Travel, accommodations, expenses, Research Funding; AstraZeneca: Honoraria, Research Funding.
